EUGenMed Project
Role of the European Institute of Women’s Health (EIWH)

Peggy Maguire
Director General
European Institute of Women’s Health
About the EIWH

• The European Institute of Women’s Health is a health NGO launched in 1996.

• The EIWH aims to ensure a gender-sensitive approach to health policy, prevention, treatment, care and research in order to reduce health inequalities and improve quality of life.

• Organisation:
  • Extensive multi-national, multi-disciplinary network of patient groups, health NGOs, researchers, gender experts, politicians, and medical professionals
  • Expert Advisory Board
Our Work Includes

- Member of EMA PCWP—meetings with PCWP and health professionals
- DG SANTE, pharmaceutical and health units
- DG Research & Innovation, DG Justice, etc.
- European Parliament members
- World Health Organization
- Working at local, national and EU levels
  - European projects and joint actions
  - Positions papers and policy briefings
- EIWH currently holds the presidency of EPHA
The EUGenMed Team

• Peggy Maguire, Director General
• Kristin Semancik, Research & Policy Officer
• Hildrun Sundseth, President
• Board Members:
  • Maeve Cusack
  • Karen Ritchie
  • Sinead Hewson

• For more information:
  • http://www.eurohealth.ie
  • info@eurohealth.ie
EIWH Role

- Stakeholder list
- Project events and meetings
  - Kick-off and launch
  - Workshop 1.4 Parts A and B
- Project Reports
- Lead of communication work package
  - Policy briefings and other materials
- Development of the roadmap
EIWH Role

• Project partners have been active in dissemination activities, such as presentations at European events and meetings
  • Presentations such as at the EMA PCWP, WHO regional meeting, Joint Action on Chronic disease, Gender Equality forum
  • Articles such as one on EUGenMed Romanian health policy journal (June 2015)
• 4 March 2015
• European Economic and Social Committee, Brussels, Belgium
• Part A: Sex and gender in medical education
• Part B: Sex and gender in medicines regulation
Please visit [http://eugemed.eu](http://eugemed.eu) or [http://eurohealth.ie](http://eurohealth.ie) for the full press release and workshop report.
Five policy briefings have been generated on specific diseases:
- CVD, lung cancer, diabetes, asthma and stroke
- The briefs are written in lay language (English) and provide some facts and examples of how S&G affects prevention, development, diagnosis and/or treatment of these diseases
- The briefs will be distributed to key stakeholders in the field, including policy makers and medical professionals, to increase awareness
Policy Briefings

POLICY BRIEF

EUROPEAN GENDER MEDICINE (EUGENMED)

Sex and Gender in Asthma

What is Asthma?
Asthma is a chronic inflammatory disorder of the lungs. Chronically inflamed airways are a hallmark of asthma and are responsible for the symptoms. The inflammation is caused by the release of chemical mediators, such as histamine and leukotrienes. These mediators cause the airways to narrow, making it difficult to breathe. Asthma can be triggered by a variety of factors, including allergies, exercise, cold air, and dust.

How Big is the Problem?
Asthma is a major public health issue. In the United States, over 25 million people have asthma, and it is the leading cause of hospitalizations for children under 18. Asthma affects people of all ages, but it is more common in children and young adults.

Why Sex and Gender Matters: Biological Differences

According to the OECD, in Europe, asthma is more common in boys than girls, but it is more mild in boys. However, the risk of asthma is higher in girls than boys. Moreover, the prevalence of asthma is higher in girls than boys. In addition, the prevalence of asthma is higher in girls than boys.

REFERENCES

Project Partners
European Institute of Women’s Health
5 Pierson Street
Dublin 2, Ireland
http://www.iewh.ie

© European Institute of Women’s Health
30 November 2015

ABOUT THE EUGENMED PROJECT

Research addressing sex and gender (S&G) in biomedical sciences and health research is emerging as a novel and highly promising field. This interaction between S&G and biological sciences is leading to different manifestations of diseases—such as inflammation, heart failure, diabetes, and rheumatic diseases in men and women. Researchers in the field will lead to novel, better targeted, and, therefore, more efficient treatment strategies than the previous global approaches toward women’s health expectancy.

The EUGENMED Project is coordinated by Chariot, Universitätsmedizin Berlin, and the University of Fribourg. The Project is funded by the European Commission under the Seventh Framework Programme and began on October 1, 2013. The Project aims to use a multi-disciplinary approach to understand the role of sex and gender differences in health and disease.

The EUGENMED Project will produce an innovative roadmap for implementation of S&G research in Europe. The results from the four workshops will be published as a report for the implementation of S&G research in Europe.

To find out more, visit the EUGENMED website: http://eugenmed.eu.
Thank you. Any questions?

European Institute of Women’s Health
33 Pearse Street, Dublin 2, Ireland
http://eurohealth.ie
+353-1-671-5691 (phone)
This project the European Gender Medicine Network (EUGenMed) has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement No. 602050